Cary Street Partners Financial LLC Grows Holdings in Eli Lilly and Company $LLY

Cary Street Partners Financial LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,543 shares of the company’s stock after acquiring an additional 492 shares during the quarter. Eli Lilly and Company comprises approximately 0.8% of Cary Street Partners Financial LLC’s holdings, making the stock its 26th biggest position. Cary Street Partners Financial LLC’s holdings in Eli Lilly and Company were worth $30,675,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares in the last quarter. State Street Corp lifted its position in Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after buying an additional 219,590 shares during the last quarter. Capital Research Global Investors lifted its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 4.1% in the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after buying an additional 574,229 shares during the last quarter. Finally, Capital International Investors lifted its position in Eli Lilly and Company by 6.1% in the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock worth $7,628,447,000 after buying an additional 579,381 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: UBS said Lilly’s late-stage retatrutide data showed strong obesity efficacy and a clear dose-response, with the highest dose producing about 28% weight loss at 80 weeks, reinforcing Lilly’s position in the fast-growing obesity market. Eli Lilly weight loss drug data supports long-term obesity market position, says UBS
• Positive Sentiment: Phase 1b Heart-2 results for VERVE-102 were reported as highly encouraging, with a single dose reducing PCSK9 by up to 88% and LDL-C by up to 62%, supporting Lilly’s case for a potential one-time treatment in high-risk cholesterol patients. A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
• Positive Sentiment: Several market commentators highlighted Lilly as a long-term growth and “must-own” type of stock, which can reinforce investor confidence and keep sentiment constructive. Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Independent stock-picking articles and hedge-fund stake updates included Lilly among attractive holdings, but these were mostly portfolio commentary rather than company-specific fundamentals. 5 Best Stocks for a Couch Potato portfolio
• Negative Sentiment: A separate lawsuit headline about drug reimbursements adds some legal overhang, though it appears less important than the recent positive pipeline news. COGIC responds after Eli Lilly files lawsuit over drug reimbursements

Eli Lilly and Company Trading Up 0.1%

Shares of NYSE:LLY opened at $1,066.59 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a market capitalization of $1.00 trillion, a PE ratio of 37.89, a PEG ratio of 1.16 and a beta of 0.48. The business has a 50 day moving average of $944.65 and a two-hundred day moving average of $1,005.65. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Ratings Changes

Several analysts have recently weighed in on LLY shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday. TD Cowen lifted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Bank of America cut their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Argus boosted their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, CICC Research boosted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.